HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Keith A. Horvath David A. Fullerton Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Horvath, K. A. Articles by Fullerton, D. A. Search for Related Content PubMed PubMed Citation Articles by Horvath, K. A. Articles by Fullerton, D. A. Related Collections Molecular biology

Ann Thorac Surg 2002;74:481-487
© 2002 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Myocardial functional recovery after fibroblast growth factor 2 gene therapy as assessed by echocardiography and magnetic resonance imaging

^a Division of Cardiothoracic Surgery, Northwestern University Medical School, Chicago, Illinois, USA
^b Selective Genetics, Inc., San Diego, California, USA

* Address reprint requests to Dr Horvath, Division of Cardiothoracic Surgery, Northwestern University Medical School, 201 E. Huron St, Galter 10-105, Chicago, IL 60611 USA
e-mail: khorvath{at}nmh.org

Presented at the Thirty-eighth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 28–30, 2002.

Background. Although it has been shown that gene therapy is capable of inducing neovascularization in ischemic myocardium, the functional significance of such therapeutic angiogenesis remains less certain. The purpose of this study was to investigate whether an experimental link could be made between the ability of a novel fibroblast growth factor 2 (FGF2) gene formulation to promote neovascularization, and its ability to restore myocardial function.

Methods. Fibroblast growth factor 2 gene was delivered by means of an adenovirus vector formulated in a collagen-based matrix to provide localized and sustained gene activity. Using a model of chronic myocardial ischemia, animals were randomized to either treatment of the ischemic area by injections of adenovirus vector-FGF2 or no treatment. Left ventricular function was assessed by rest and dobutamine stress echocardiography as well as contrast-enhanced and cine magnetic resonance imaging scans. Studies were repeated 6 weeks after treatment. Arteriogenesis was assessed by quantifying the total arteriolar wall area present in treated areas, using anti--actin immunohistochemistry and subsequent morphometric analyses.

Results. Echocardiographic results demonstrated a significant restoration of myocardial function in FGF2 gene-treated areas as measured by myocardial wall thickening (0.38 ± 0.08 cm pretreatment versus 0.76 ± 0.09 cm posttreatment; p < 0.05). This was demonstrated by comparing the ischemic zones of FGF2 gene-treated versus control-treated animals, as well as by comparing ischemic with nonischemic zones in individual animals This functional improvement was confirmed by cine magnetic resonance imaging, in which 68% (147 of 216) of the treated segments showed improvement in wall motion and there was no change in the untreated segments. Fibroblast growth factor 2 gene treatment also enhanced arteriogenesis within the ischemic zone, as FGF2 gene-treated animals showed a 340% increase in the total arteriolar wall area present versus control-treated animals.

Conclusions. The function of ischemic myocardium can be restored by a novel FGF2 gene delivery method using a gene-activated matrix. The increased arteriogenesis as a result of FGF2 gene therapy leads to restoration of this myocardial function.

This article has been cited by other articles:

				M. C. van Oostrom, O. van Oostrom, P. H. A. Quax, M. C. Verhaar, and I. E. Hoefer Insights into mechanisms behind arteriogenesis: what does the future hold? J. Leukoc. Biol., December 1, 2008; 84(6): 1379 - 1391. [Abstract] [Full Text] [PDF]

				K. A. Horvath and Y. Zhou Transmyocardial Laser Revascularization and Extravascular Angiogenetic Techniques to Increase Myocardial Blood Flow Card. Surg. Adult, January 1, 2008; 3(2008): 733 - 752. [Full Text]

				K. A. Horvath, C. Y. J. Lu, E. Robert, G. F. Pierce, R. Greene, B. A. Sosnowski, and J. Doukas Improvement of myocardial contractility in a porcine model of chronic ischemia using a combined transmyocardial revascularization and gene therapy approach J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1071 - 1077. [Abstract] [Full Text] [PDF]

				J. C. Chachques, F. Duarte, B. Cattadori, A. Shafy, N. Lila, G. Chatellier, J.-N. Fabiani, and A. F. Carpentier Angiogenic growth factors and/or cellular therapy for myocardial regeneration: A comparative study J. Thorac. Cardiovasc. Surg., August 1, 2004; 128(2): 245 - 253. [Abstract] [Full Text] [PDF]

				J. Hijjawi, J. E. Mogford, L. A. Chandler, K. J. Cross, H. Said, B. A. Sosnowski, and T. A. Mustoe Platelet-Derived Growth Factor B, but Not Fibroblast Growth Factor 2, Plasmid DNA Improves Survival of Ischemic Myocutaneous Flaps Arch Surg, February 1, 2004; 139(2): 142 - 147. [Abstract] [Full Text] [PDF]

				E. Deindl, I. E. Hoefer, B. Fernandez, M. Barancik, M. Heil, M. Strniskova, and W. Schaper Involvement of the Fibroblast Growth Factor System in Adaptive and Chemokine-Induced Arteriogenesis Circ. Res., March 21, 2003; 92(5): 561 - 568. [Abstract] [Full Text] [PDF]